Wall Street analysts expect CymaBay Therapeutics (NASDAQ:CBAY) to report $5.00 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for CymaBay Therapeutics’ earnings. CymaBay Therapeutics reported sales of $4.79 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.4%. The firm is expected to report its next quarterly earnings results on Thursday, May 10th.
On average, analysts expect that CymaBay Therapeutics will report full-year sales of $5.00 million for the current fiscal year. For the next fiscal year, analysts forecast that the company will report sales of $23.67 million per share, with estimates ranging from $15.00 million to $36.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.06. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $1.25 million.
In other CymaBay Therapeutics news, Director Kurt Von Emster sold 218,057 shares of the company’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $15.89, for a total value of $3,464,925.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carl Goldfischer sold 15,000 shares of the company’s stock in a transaction dated Thursday, March 22nd. The shares were sold at an average price of $13.03, for a total transaction of $195,450.00. Following the completion of the sale, the director now directly owns 9,340 shares of the company’s stock, valued at $121,700.20. The disclosure for this sale can be found here. Insiders sold 815,648 shares of company stock valued at $10,283,751 in the last ninety days. Corporate insiders own 15.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of CBAY. Schwab Charles Investment Management Inc. acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at about $115,000. Goldman Sachs Group Inc. acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at about $197,000. Virtu Financial LLC lifted its holdings in CymaBay Therapeutics by 56.2% in the 4th quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 8,899 shares during the last quarter. Sigma Planning Corp lifted its holdings in CymaBay Therapeutics by 82.0% in the 4th quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 12,300 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in CymaBay Therapeutics by 7,729.2% in the 4th quarter. Wells Fargo & Company MN now owns 39,146 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 38,646 shares during the last quarter. 58.15% of the stock is owned by institutional investors.
CymaBay Therapeutics stock opened at $13.12 on Tuesday. The stock has a market cap of $789.77, a PE ratio of -16.61 and a beta of 2.06. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.35 and a quick ratio of 6.35. CymaBay Therapeutics has a one year low of $3.16 and a one year high of $15.59.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/04/17/brokerages-anticipate-cymabay-therapeutics-cbay-will-post-quarterly-sales-of-5-00-million.html.
About CymaBay Therapeutics
Cymabay Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. It engages in developing seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.